EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
Results from the pivotal phase III ARCADIA 1 and 2 and OLYMPIA 1 studies evaluating the safety and efficacy of nemolizumab in moderate to severe atopic dermatitis and prurigo nodularis will be presented for the first time as late-breaking abstracts.1,2 New dat


